The purpose of this study is to evaluate the effectiveness of Focal-Fusion Bx at detecting
clinically significant prostate cancer in a standard clinical environment.
The objective of this study is to determine the effectiveness of the Focal-Fusion Bx device
at finding clinically relevant prostate cancer.
A multiparametric MRI examination will be carried out prior to study enrollment. Probable
cancerous regions (regions of interest, ROI) will be identified, and these ROIs will be used
as targets during the biopsy.
Three prostate sampling methods will be conducted in the same session on all patients. These
i) Focal-Fusion Bx targeted biopsy ii) Cognitive fusion targeted biopsy and iii) Systematic
(untargeted) biopsy. Trans-rectal ultrasound (TRUS) imaging will be conducted with BK Flex
Focus Ultrasound system (Analogic Corporation, Peabody, MA).
Primary hypothesis: The technique used to acquire the biopsy samples will impact the
proportion of clinically relevant cancers by improving the specificity of detecting
clinically significant cancers. It is hypothesized that Focal-Fusion Bx biopsies will
diagnose more high risk cancers and fewer low-risk cancers than non-targeted systematic
- Adult male subjects up to 80 years of age
- Candidates for fusion biopsy
- Elevated PSA levels
- MP-MRI with lesions having a Prostate Imaging Reporting and Data System (PI-RADS)
score greater than or equal to 3 (determined by a trained radiologist)
- Subject is willing and able to read, understand and sign the Informed Consent Form
- Previous treatment for prostate cancer
- Any contraindication to a standard TRUS prostate biopsy procedure
- Refusal to sign the Informed Consent document